Prism MarketView

December 06, 2023 at 9:37 am

Aussie Biotech Targeting E. Coli and Campylobacter Infections with New Oral Therapeutic

Australian biotechnology company, Immuron Limited (Nasdaq: IMRN) has initiated the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) in… [Read More]

December 05, 2023 at 10:12 am

Clearmind Successfully Treats Cocaine Addiction with Psychedelic Molecule; Shares Soar 70%

Clearmind Medicine Inc. (Nasdaq: CMND) has achieved positive results in addiction treatment for its revolutionary treatment targeting cocaine addiction. The company’s innovative psychedelic molecule, 5-Methoxy-2-aminoindane… [Read More]

December 05, 2023 at 9:52 am

IceCure’s Patient-Friendly, Non-Surgical Cancer Treatment

IceCure Medical Ltd. (Nasdaq: ICCM) has published results of an independent study demonstrating safety and efficacy of its ProSense® System. The study, published in the… [Read More]

December 04, 2023 at 10:50 am

Alterity Therapeutics Shows Positive Efficacy in Parkinson’s Disease Treatment; Shares Surge 160%

Alterity Therapeutics (Nasdaq: ATHE) has presented promising new data on the effect of ATH434 in a Parkinson’s disease primate model at the Future of Parkinson’s… [Read More]

December 04, 2023 at 10:31 am

Biotech Breakfast – Healthcare Equities Close Higher, Major Healthcare Groups Fare Well; Altimmune Soars while Pfizer Falls on Obesity Clinical Updates

Healthcare equities closed higher on Friday afternoon, with most major healthcare groups faring well. Healthcare closed up +0.11% versus the S&P 500 which rose +0.54%…. [Read More]

December 04, 2023 at 10:25 am

MIRA Pharmaceuticals: AI Ushering in New Era of Drug Discovery and Analysis

MIRA Pharmaceuticals (Nasdaq: MIRA) has released new data from artificial intelligence (AI) simulations showing that there may be significant potential advantages to the therapeutic potential… [Read More]

December 01, 2023 at 1:27 pm

Biora Therapeutics Offers Hope to 1.8 Million Americans with Inflammatory Bowel Disease

Biora Therapeutics (Nasdaq: BIOR) has received FDA clearance for its Investigational New Drug (IND) application for BT-600, a drug/device combination for the treatment of moderate… [Read More]

December 01, 2023 at 10:35 am

Positive Topline Results for Altimmune in Obesity Drug Trial; Shares up 41% in Morning Trading

Altimmune, Inc. (Nasdaq: ALT) has reported positive topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide. Over 50% of subjects achieved at… [Read More]

November 30, 2023 at 9:09 am

Abeona Therapeutics Granted FDA Priority Review for Rare Disease Treatment

Abeona Therapeutics (Nasdaq: ABEO) has been granted Priority Review for its Biologics License Application (BLA) for pz-cel (prademagene zamikeracel), the company’s investigational autologous, COL7A1 gene-corrected… [Read More]

November 30, 2023 at 8:35 am

Biodexa Asset Offers Potential to ‘Radically Improve’ Treatment for Diabetes Patients

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) has entered into an agreement for the rights to develop and commercialize tolimidone under an exclusive, worldwide license from Melior… [Read More]

November 29, 2023 at 11:11 am

Vivos Therapeutics Receives FDA Approval for Oral Sleep Apnea Device; Shares Skyrocket 270%

Medical device and technology company, Vivos Therapeutics (Nasdaq: VVOS) has been granted 510(k) clearance by the FDA for treating severe obstructive sleep apnea (OSA) in… [Read More]

November 29, 2023 at 11:07 am

Department of Defense to Study Seelos Therapeutics’ Ketamine Compound as PTSD Treatment

Seelos Therapeutics, Inc. (Nasdaq: SEEL) has announced that its drug candidate, SLS-002 (intranasal racemic ketamine), has been selected for inclusion in a clinical trial to… [Read More]

Tag: BIO TECH